Search alternatives:
lower decrease » larger decrease (Expand Search), linear decrease (Expand Search), we decrease (Expand Search)
teer decrease » greater decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 3,621 - 3,640 results of 18,676 for search 'significantly ((((((lower decrease) OR (teer decrease))) OR (a decrease))) OR (mean decrease))', query time: 0.67s Refine Results
  1. 3621
    IFA effectively reduced the production of <i>K</i>. <i>pneumoniae</i> capsule.

    IFA effectively reduced the production of <i>K</i>. <i>pneumoniae</i> capsule. by Tingting Wang (123983)

    Published 2025
    Save to List
    Saved in:
  2. 3622
    IFA reduced the virulence of hypervirulent <i>K</i>. <i>pneumoniae</i> in <i>G</i>. <i>mellonella</i> larvae.

    IFA reduced the virulence of hypervirulent <i>K</i>. <i>pneumoniae</i> in <i>G</i>. <i>mellonella</i> larvae. by Tingting Wang (123983)

    Published 2025
    Save to List
    Saved in:
  3. 3623
    IFA did not affect LPS-induced inflammation response.

    IFA did not affect LPS-induced inflammation response. by Tingting Wang (123983)

    Published 2025
    Save to List
    Saved in:
  4. 3624
    IFA abrogated capsule-associated hypermucoviscosity phenotypes of hypervirulent <i>K</i>. <i>pneumoniae</i>.

    IFA abrogated capsule-associated hypermucoviscosity phenotypes of hypervirulent <i>K</i>. <i>pneumoniae</i>. by Tingting Wang (123983)

    Published 2025
    Save to List
    Saved in:
  5. 3625
    IFA sensitized hypervirulent <i>K</i>. <i>pneumoniae</i> to complement-mediated killing by inhibiting capsule.

    IFA sensitized hypervirulent <i>K</i>. <i>pneumoniae</i> to complement-mediated killing by inhibiting capsule. by Tingting Wang (123983)

    Published 2025
    Save to List
    Saved in:
  6. 3626
    Vertebral cancellous tissueμCT parameters are not significantly affected by aging from 16 to 21 weeks, housing type, or microgravity.

    Vertebral cancellous tissueμCT parameters are not significantly affected by aging from 16 to 21 weeks, housing type, or microgravity. by Rukmani Cahill (20939813)

    Published 2025
    “…(G) μCT volumetric reconstructions of a representative sample from each group show a slight decrease in bone parameters from FL mice, which are not deemed significant by statistical testing.…”
    Save to List
    Saved in:
  7. 3627
    IFA treatment facilitated host immune clearance of hypervirulent <i>K</i>. <i>pneumoniae</i> by targeting capsule.

    IFA treatment facilitated host immune clearance of hypervirulent <i>K</i>. <i>pneumoniae</i> by targeting capsule. by Tingting Wang (123983)

    Published 2025
    Save to List
    Saved in:
  8. 3628
    IFA effectively limited bacterial dissemination and protected mice from lethal hypervirulent <i>K</i>. <i>pneumoniae</i> pneumonia.

    IFA effectively limited bacterial dissemination and protected mice from lethal hypervirulent <i>K</i>. <i>pneumoniae</i> pneumonia. by Tingting Wang (123983)

    Published 2025
    Save to List
    Saved in:
  9. 3629
    Safranin O fast green staining results of cartilage tissue in different groups of rat PTOA (A: normal group, B: mild PTOA group, C: severe PTOA group).

    Safranin O fast green staining results of cartilage tissue in different groups of rat PTOA (A: normal group, B: mild PTOA group, C: severe PTOA group). by Peng-fei Han (694841)

    Published 2025
    Save to List
    Saved in:
  10. 3630
    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  11. 3631
    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  12. 3632
    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  13. 3633
    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  14. 3634
    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  15. 3635
    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  16. 3636
    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  17. 3637
    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  18. 3638
    Image 4_The immunomodulatory and antitumor properties of the bacterial metalloprotease Oligopeptidase A are mediated by TLR4/MyD88/TRIF and MAPK signaling pathways.tiff

    Image 4_The immunomodulatory and antitumor properties of the bacterial metalloprotease Oligopeptidase A are mediated by TLR4/MyD88/TRIF and MAPK signaling pathways.tiff by Priscila Silva (556743)

    Published 2025
    “…</p>Results<p>Heat-inactivated OpdA significantly reduced metastasis, dependent on tumor-specific CD4+ and CD8+ T cells and IFN-γ, both locally and systemically, with decreased IL-10 levels suggesting a proinflammatory environment. …”
    Save to List
    Saved in:
  19. 3639
    Image 2_The immunomodulatory and antitumor properties of the bacterial metalloprotease Oligopeptidase A are mediated by TLR4/MyD88/TRIF and MAPK signaling pathways.tiff

    Image 2_The immunomodulatory and antitumor properties of the bacterial metalloprotease Oligopeptidase A are mediated by TLR4/MyD88/TRIF and MAPK signaling pathways.tiff by Priscila Silva (556743)

    Published 2025
    “…</p>Results<p>Heat-inactivated OpdA significantly reduced metastasis, dependent on tumor-specific CD4+ and CD8+ T cells and IFN-γ, both locally and systemically, with decreased IL-10 levels suggesting a proinflammatory environment. …”
    Save to List
    Saved in:
  20. 3640
    Image 1_The immunomodulatory and antitumor properties of the bacterial metalloprotease Oligopeptidase A are mediated by TLR4/MyD88/TRIF and MAPK signaling pathways.tif

    Image 1_The immunomodulatory and antitumor properties of the bacterial metalloprotease Oligopeptidase A are mediated by TLR4/MyD88/TRIF and MAPK signaling pathways.tif by Priscila Silva (556743)

    Published 2025
    “…</p>Results<p>Heat-inactivated OpdA significantly reduced metastasis, dependent on tumor-specific CD4+ and CD8+ T cells and IFN-γ, both locally and systemically, with decreased IL-10 levels suggesting a proinflammatory environment. …”
    Save to List
    Saved in:

Search Tools: